Latest News & Updates of Loncom Pharma

Loncom Pharmaceutical wrapped up its 2026 Safety Production Month with record participation, practical emergency drills, and a knowledge contest. A comprehensive hazard inspection per AQ3067-2026 was completed. The company reinforces that rigorous safety management is the bedrock of drug quality and patient trust across all operations.

Biocom made a strong appearance at CPHI China 2026, hosting over 100 clients and securing dozens of cooperation intentions during the three-day event. Leveraging its full‑industry‑chain strengths and ICH‑aligned R&D, cGMP quality systems, and ISO dual certifications, the company showcased its integrated capabilities in API and FDF development, manufacturing, and global registration, while capturing key trends such as digital pharma and low‑carbon synthesis. Looking ahead, Biocom will continue to deepen its focus on high‑end APIs, accelerate AI‑driven and green manufacturing, and join global partners in driving high‑quality, sustainable growth for the pharmaceutical industry.

Biocom Pharma will participate in CPHI China 2026 in Shanghai, showcasing APIs, FDFs, CDMO, technology transfer, and global registration services. The company invites global partners to visit Booth W6C12 to explore collaboration opportunities in development, manufacturing, and commercialization, strengthening long-term partnerships and accelerating pharmaceutical market access worldwide efforts worldwide.

Biocom participated in FCE Pharma 2026 in São Paulo, Brazil, strengthening connections with pharmaceutical partners across Latin America. Through discussions on registration, market access, supply chains, and quality systems, the company secured multiple cooperation opportunities, expanded its regional network, and reinforced its commitment to long-term growth in the Latin American market.